Saving Lives Through Innovations in Targeted Protein Degradation (TPD) Therapeutics.
Ubix Therapeutics is a clinical-stage biotechnology company with comprehensive capabilities in TPD therapeutics, spanning from discovery to clinical studies. Our proprietary TPD platform technology, Degraducer®, harnesses the body’s natural protein degradation machinery to eliminate diseased proteins, achieving near-complete inactivation of disease-causing pathways.
We have established a robust, wholly owned and partnered degrader pipeline focused on targeted and immuno-oncology areas. Our wholly owned programs include:
• UBX-303-1, a Phase 1-stage, potential best-in-class BTK degrader for treating relapsed or refractory B-cell malignancies.
• UBX-106, a preclinical-stage, potential first-in-class SHP2 degrader designed to treat a broad spectrum of MAPK signaling-driven solid tumors.
Additionally, the IND-enabling study for UBX-103, AR degrader program which was out-licensed to Yuhan in July 2024, is currently underway.
We believe our degrader programs can effectively address a broad range of drug resistance mutations and overcome residual activation of disease-causing signaling pathways. Our growing pipeline also includes programs targeting difficult-to-address proteins and the development of degrader-antibody conjugates.
For more information, please visit http://en.ubixtrx.com/ or contact us at info@ubixtrx.com.
Company Details
- Employees
- 9
- Founded
- 2018
- Address
- 7 Beobwon-Ro 11-Gil, Songpa-Gu, C-Dong,unit 1401,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ubixtrx.com/
- Keywords
- Pacific Laboratory Products.
- HQ
- Seoul, Seoul
Ubix Therapeutics, Inc. Questions
Ubix Therapeutics, Inc.'s website is http://www.ubixtrx.com/
Ubix Therapeutics, Inc.'s LinkedIn profile is https://kr.linkedin.com/company/ubix-therapeutics
Ubix Therapeutics, Inc. has
9 employees.
View email and phone details for 9
employees at Ubix Therapeutics, Inc..
Ubix Therapeutics, Inc.'s industry is
Biotechnology Research
Ubix Therapeutics, Inc.'s top competitors are
Urma Pharma,
Vaxcellbio 박셀바이오,
Nurix,
Plabio,
Pacific Laboratory Products,
Roche,
Agios Pharmaceuticals,
Byroco,
Y-Biologics,
Beigene.
Ubix Therapeutics, Inc.'s categories are Biotechnology Research
Ubix Therapeutics, Inc.'s founding year is 2018
